Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV‐related liver cirrhosis and hepatocellular carcinoma. The use of direct‐acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.
Bibliographical noteFunding Information:
Funding: The authors acknowledge grant support of the National Research Foundation of Korea (NRF) (2017R1A2A1A17069782, E.C.S; 2017M3A9G6068245, S.K; 2019R1I1A1A01059642, P.S.S; 2017M3A9G6068246, M.P.W; and 2014R1A2A1A11052535, M.P.W), the National Research Council of Science & Technology of Korea (CRC‐16‐01‐KRICT, S.J.K), National Natural Science Foundation of China (31670172, J.Z), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010205, J.Z), and Japan Agency for Medical Research and Development (AMED) Grants (JP19fk0210036j0002, K.W).
© 2020 by the authors.
All Science Journal Classification (ASJC) codes
- Infectious Diseases